A new hormonal therapy for prostate cancer is under expedited FDA review
In June, the US Food and Drug Administration (FDA) launched an accelerated review of a promising new drug for advanced prostate cancer. Called relugolix, it suppresses testosterone and other hormones that speed the cancer’s growth. If approved, this new type of hormonal therapy is expected to set a new standard of care for the disease. Doctors give hormonal therapies when a man’s tumor is metastasizing (spreading beyond the prostate), or if his PSA levels start rising after surgery or radiation. The most commonly used hormonal therapies, called LHRH agonists, will eventually lower testosterone levels in blood. ...
Source: Harvard Health Blog - July 13, 2020 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Prostate Knowledge Treatments HPK Source Type: blogs